An observational study in Sarcoma, Soft Tissue, Retroperitoneal Neoplasms and Surgery, sponsored by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano. Status unknown. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-07.
Sponsored by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Observational
No prospective data exist about long term morbidity and quality of life after multivisceral surgical resection for retroperitoneal soft tissue sarcoma (RSTS).
In order to assess the safety of this surgical approach and the effect on the Quality of Life over the long period we propose a prospective observational study.
The hypothesis is that the surgical treatment has no significant impact in determining a lower Quality of Life in the long term.
Objectives Primary objective Estimate the difference between baseline and 4 and 12 months scores of the "global health status / QoL" scale in patients primarily treated for localized RSTS, as determined in QLQ-C30 version 3.0.
Secondary objectives
Eligibility Inclusion criteria
Exclusion criteria
Study description This is an observational study aimed to prospectively evaluate the long term morbidity of aggressive surgical approach to RSTS and the impact over the patients' quality of life. Consecutive patients candidate to surgery for primary RSTS will be offered to be enrolled. We plan to include all the RSTS patients consecutively operated on for primary retroperitoneal sarcoma from first accrual on up to the 24 months after the study start.
At the entrance of the study, an informed written consent will be obtained. Study participants will be asked to complete four self-filled in one-off questionnaires (see "Study parameters" paragraph).
Study parameters Study parameters EORTC QLQ-CR29 and EORTC QLQ C30 questionnaires (baseline, 4 mos, 12 mos) LEFS questionnaire (baseline, 4 mos, 12 mos) BPI questionnaire (baseline, 4 mos, 12 mos) DN4 questionnaire (baseline, 4 mos, 12 mos) Serum creatinin (baseline, 4 mos, 12 mos) Morbidity events (4 mos, 12 mos) Neurologic exam of lower limbs (baseline, 4 mos, 12 mos) Disease status (4 mos, 12 mos)
* In case of preoperatory complementary treatment, the questionnaires will be administrated just before the beginning of the treatment.
Statistical considerations Statistical analyses
Interim Analysis We plan to performed an interim cross-sectional analysis at the end of patient enrollment in order to describe the study population at baseline, according to the primary and secondary endpoints.
Sample size
We plan to include all the RSTS patients consecutively operated on for primary retroperitoneal sarcoma from first accrual on for the next 24 months (about 60 patients estimated.
A sample size of 60 patients allows the estimation of a two-sided 95,0% confidence interval for the paired difference between baseline and post treatment scores with a precision (half CI width) of 0.25 times the standard deviation of the difference.
1,607 studies on the registry are indexed under Sarcoma; 366 are open to participants now.
This study's enrollment of 60 is below the median of 120 across 218 observational studies indexed under Sarcoma.
Browse Sarcoma studies →Fondazione IRCCS Istituto Nazionale dei Tumori, Milano is the lead sponsor of 172 studies on the registry; 50 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Primary retroperitoneal sarcoma candidated to multivisceral resection
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Global Health Status
Change between baseline and 4 and 12 months scores of the "global health status / QoL" scale in patients primarily treated for localized RSTS, as determined in QLQ-C30 version 3.0.
Time frame: 4 and 12 months postoperatively
Renal failure
Evaluate the long term morbidity of aggressive surgical approach to RSTS in terms of renal failure.
Time frame: 12 months postoperatively
DN4 questionnaire for neuropathic pain
Change between baseline and 4 and 12 months scores
Time frame: 4 and 12 months postoperatively
LEFS questionnaire for lower limb function
Change between baseline and 4 and 12 months scores
Time frame: 4 and 12 months postoperatively
BPI questionnaire for chronic pain
Change between baseline and 4 and 12 months scores
Time frame: 4 and 12 months postoperatively
QLC-C30, Functional Scales
Change between baseline and 4 and 12 months scores
Time frame: 4 and 12 months postoperatively
QLC-C29
Change between baseline and 4 and 12 months scores
Time frame: 4 and 12 months postoperatively
No study locations are listed for this record.
Plan to share: Undecided
The record gives a start of Jan 2014, a primary completion of Jan 2016 and a completion of Jan 2021. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano →